Tibetan medicine composition for treating rhinitis and preparation method thereof

Abstract

The invention discloses a Tibetan medicine composition for treating rhinitis and a preparation method thereof. The Tibetan medicine composition is prepared from the following raw materials: cortex berberidis, fructus chebulae, flos carthami, borneol, artificial bear gall and artificial musk, and the mass ratio of the cortex berberidis to the fructus chebulae to the flos carthami to the borneol to the artificial bear gall to the artificial musk is (250-350): (150-250): (150-250): (15-25): (0.5-3): (0.5-3). The bioavailability of the medicine is improved through an elaborately designed formula and a preparation process, and an expected treatment effect can be achieved under a small dosage, so that potential side effects are reduced.

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to a Tibetan medicine composition for treating rhinitis and a preparation method thereof. Background Art

[0002] Rhinitis, also known as allergic rhinitis or allergic rhinitis (AR), is an inflammatory disease in which the nasal mucosa and submucosal tissues become congested or edematous, manifested by symptoms such as sneezing, nasal congestion, runny nose, and nasal itching. Frequent onset affects the patient's mental stress and increases the economic burden. Currently, the main treatments are Western medicine, immunotherapy, and surgical treatment. One of the common treatments for allergic rhinitis is drug therapy, which can effectively relieve symptoms such as nasal congestion and sneezing, but long-term use of steroid drugs can cause side effects such as osteoporosis and increased blood sugar.

[0003] Now the air pollution is serious, and the number of people suffering from rhinitis is increasing. If not treated in time, it is easy to cause sinusitis or asthma and other diseases. Oral treatment of Chinese medicine is based on "holistic concept" and "differentiation and treatment". Although it is relatively safe, the treatment course is time-consuming; Western medicine takes drugs according to symptoms, and the treatment effect is obvious, but it is easy to have disadvantages such as dependence and drug resistance.

[0004] Therefore, there is an urgent need for a pharmaceutical composition with good rhinitis treatment effect and high safety. Summary of the invention

[0005] The purpose of the present invention is to provide a Tibetan medicine composition for treating rhinitis and a preparation method thereof, so as to solve the problems that the traditional Chinese medicine for treating rhinitis takes a long time to treat and the western medicine is easy to produce drug dependence.

[0006] To achieve the above-mentioned purpose, the present invention provides a first aspect of a Tibetan medicine composition for treating rhinitis. The raw materials of the Tibetan medicine composition include barberry bark, terminalia chebula, safflower, borneol, artificial bear bile and artificial musk. The mass ratio of barberry bark, terminalia chebula, safflower, borneol, artificial bear bile and artificial musk is (250-350): (150-250): (150-250): (15-25): (0.5-3): (0.5-3).

[0007] Preferably, the mass ratio of berberis bark, terminalia chebula, safflower, borneol, artificial bear gall and artificial musk is 300:200:200:20:1:1.

[0008] The functions of various raw materials in the present invention are as follows:

[0009] Berberis bark is the dried inner bark of Berberis kansuensis CKSchneid. or Berberis dictyophylla Franch. and other plants of the same genus. It is cold in nature and bitter in taste. In Tibetan medicine theory, Berberis bark has the effect of astringing yellow water and can be used to treat yellow water disease and improve related symptoms.

[0010] Terminalia chebula Retz is the dried fruit of the plant Terminalia chebula Retz. of the Combretaceae family. It has a bitter taste and a neutral nature. It has the effects of nourishing the body, raising stomach fire, aiding digestion, soothing the mind, and improving eyesight.

[0011] Safflower is the dried flower of Carthamus tinctorius L., a plant of the Asteraceae family. It tastes sweet, slightly bitter, cool in nature, and has strong effects. It has the effects of clearing heat, promoting blood circulation, and nourishing the body.

[0012] Borneol is a crystal obtained from the resin and volatile oil of the Dipterocarpaceae plant borneol (Dryobalanops aromatica Gaertn.f.). It tastes bitter and pungent, has a cool nature, and has the effects of clearing heat, relieving inflammation, and reducing fever.

[0013] Artificial bear bile tastes bitter and slightly sweet, and tastes sweet after digestion. It is cold in nature and has the effects of clearing away heat and detoxifying, calming the nerves, relieving pain, promoting bile secretion and improving eyesight, strengthening the stomach, and killing insects.

[0014] Artificial musk tastes bitter and spicy, and is cool and light in nature. It has the effects of detoxification, anti-inflammatory, analgesic and insect repellent.

[0015] Preferably, the raw materials of the Tibetan medicine composition also include Tween-80, sodium chloride, phenoxyethanol and triethanolamine.

[0016] The second aspect of the present invention provides a method for preparing a Tibetan medicinal composition for treating rhinitis, comprising the following steps:

[0017] S1: Preparation of Berberis bark paste

[0018] The berberis bark coarse powder is added into purified water for water extraction, and then concentrated and purified to obtain a berberis bark thick paste;

[0019] S2: Preparation of Terminalia chebula paste and safflower paste

[0020] The terminalia chebula is crushed, and then added into an ethanol solution 1 for heating and reflux, after the alcohol extraction is completed, the residue and the extract 1 are obtained by filtering, and the extract 1 is concentrated to obtain a first thick paste;

[0021] The medicinal residue is added into redistilled water for decoction, after the decoction is completed, the residue and the second extract are obtained by filtering, and the second extract is concentrated to obtain a second thick paste;

[0022] The first thick paste and the second thick paste are combined to obtain a total thick paste, and the total thick paste is purified to obtain a terminalia chebula thick paste;

[0023] The preparation process of safflower thick paste is the same as that of terminalia chebula thick paste;

[0024] S3: Preparation of borneol aqueous solution

[0025] Add borneol into redistilled water and stir to dissolve to obtain a borneol aqueous solution;

[0026] S4: Extraction of artificial musk and artificial bear bile

[0027] Adding artificial musk into the second ethanol solution and heating it under reflux, filtering to obtain a filtrate after the alcohol extraction is completed, and concentrating the filtrate to obtain an artificial musk concentrate;

[0028] The preparation process of artificial bear bile concentrate is the same as that of artificial musk concentrate;

[0029] S5: Preparation of Tibetan medicine composition

[0030] The berberis bark paste, the terminalia chebula paste, the safflower paste and the mixed solution are combined, redistilled water is added, the mixture is stirred evenly, the supernatant is taken by centrifugation, and redistilled water is added to obtain a Tibetan medicine combination extract, sodium chloride, phenoxyethanol and triethanolamine are added to the Tibetan medicine combination extract, the mixture is stirred evenly, the supernatant is taken by centrifugation and quantified, and then sterilized to obtain a Tibetan medicine composition.

[0031] Preferably, in step S1, the solid-liquid ratio of berberis bark coarse powder and purified water is 1 g: (15-25) mL, the liquids are combined after three water extractions, and then heated and concentrated at 40-80° C. to obtain an extract, and then redistilled water is added to the extract, heated in a water bath at 40-80° C. to dissolve, and then concentrated and purified to obtain a berberis bark thick paste.

[0032] Preferably, in step S2, the mass volume ratio of terminalia chebula and ethanol solution one is 1g: (6-10)mL, the concentration of ethanol solution one is 75-85wt%, the heating temperature is 85-95°C, the number of reflux times is more than two times, each reflux time is 2-3h, and the concentration temperature of extract one is 40-80°C;

[0033] The mass volume ratio of the medicinal residue and redistilled water is 1g: (8-15)mL. The mixture is decocted twice, each time for 1-3h. The concentration temperature of the second extract is 40-80°C.

[0034] Preferably, in step S2, the purification process of the total thick paste is:

[0035] Anhydrous ethanol is added to the total thick paste to make the alcohol content reach 60-70%, and the mixture is stirred evenly. After standing for 12-48 hours, the supernatant is taken out, and the precipitate is centrifuged at 5-10° C. and 5000-8000 rpm for 10-20 minutes. The supernatant obtained by centrifugation and the supernatant obtained by standing are mixed, and then concentrated. Redistilled water is added and stirred evenly, and the mixture is stood, centrifuged and concentrated again to obtain a terminalia chebula thick paste or a safflower thick paste.

[0036] Preferably, in step S3, the mass volume ratio of borneol to redistilled water is 1 g:(60-100) mL.

[0037] Preferably, in step S4, the extraction process of artificial musk is the same as the extraction process of artificial bear bile;

[0038] The mass volume ratio of artificial musk and ethanol solution 2 is 1g:(10-20)mL, the concentration of ethanol solution 2 is 90-98wt%, the heating temperature is 85-95°C, the reflux times is more than twice, each reflux time is 2-3h, and the concentration temperature is 40-80°C.

[0039] Preferably, in step S4, the volume ratio of the artificial musk concentrate to Tween-80 is (400-600):1, and the volume ratio of the artificial bear bile concentrate to Tween-80 is (400-600):1.

[0040] Preferably, in step S5, the added amounts of sodium chloride, phenoxyethanol and triethanolamine account for 0.5-1.5%, 0.5-2% and 0.5-2% of the Tibetan medicine combination extract in a 1 g / mL crude drug amount, respectively.

[0041] Therefore, the present invention adopts the above-mentioned Tibetan medicine composition for treating rhinitis and its preparation method, which has the following beneficial effects:

[0042] (1) The raw materials of the composition of the present invention have a specific ratio. Under this ratio, the components complement each other and work together on different pathological links of rhinitis, thereby achieving a better therapeutic effect.

[0043] (2) The present invention optimizes the extraction conditions according to the characteristics of different medicinal materials through different extraction methods such as water extraction and alcohol extraction to maximize the acquisition rate of effective ingredients.

[0044] (3) The pharmaceutical composition of the present invention has no obvious cytotoxicity at a concentration lower than 0.5 mg / mL, indicating that it is highly safe for human cells. The present invention improves the bioavailability of the drug through a carefully designed formulation and preparation process, and can achieve the expected therapeutic effect at a smaller dose, thereby reducing potential side effects.

[0045] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 The effect of each drug combination on the survival rate of human nasal mucosal epithelial cells (*p<0.05);

[0047] Figure 2 The effect of different concentrations of LPS on the expression of inflammatory factors in nasal mucosal epithelial cells (*p<0.05);

[0048] Figure 3 The intervention effects of each drug combination on rhinitis (* compared with the normal group, p<0.05; # compared with the model group, p<0.05). DETAILED DESCRIPTION

[0049] The present invention will be further described below. It should be noted that this embodiment is based on the technical solution and provides a detailed implementation method and a specific operation process, but the present invention is not limited to this embodiment.

[0050] Example 1

[0051] A method for preparing a Tibetan medicine composition for treating rhinitis comprises the following steps:

[0052] S1: Raw material composition design

[0053] The raw materials of the Tibetan medicine composition in this embodiment include barberry bark, terminalia chebula, safflower, borneol, artificial bear gall and artificial musk, and the mass ratio of barberry bark, terminalia chebula, safflower, borneol, artificial bear gall and artificial musk is 300:200:200:20:1:1; the total mass of barberry bark, terminalia chebula, safflower, borneol, artificial bear gall and artificial musk is 4000g;

[0054] S2: Preparation of Berberis bark paste

[0055] According to the solid-liquid ratio of berberis bark crude powder and purified water being 1g:20mL, 300g of berberis bark crude powder was added to purified water for water extraction at a water extraction temperature of 90°C. After three water extractions, the liquids were combined, and then heated and concentrated at 60°C to obtain an extract. Then, redistilled water was added to the extract at a volume ratio of the extract to redistilled water of 1:10. After heating in a water bath at 45°C to dissolve, the extract was concentrated and purified to obtain a berberis bark thick paste.

[0056] S3: Preparation of Terminalia chebula paste and safflower paste

[0057] S31: 200 g of Terminalia chebula was crushed, and then added into ethanol solution 1 for heating and reflux, the mass volume ratio of Terminalia chebula and ethanol solution 1 was 1 g: 8 mL, the concentration of ethanol solution 1 was 80 wt %, the heating temperature was 90° C., the reflux times were twice, and the reflux time for each time was 2 h. After the alcohol extraction was completed, the residue and the extract solution 1 were obtained by filtration, and the extract solution 1 was concentrated at 45° C. to obtain a first thick paste;

[0058] The residue is added into redistilled water for decoction, the mass volume ratio of the residue to the redistilled water is 1 g: 10 mL, and the decoction is performed twice, each time for 1 hour. After the decoction is completed, the residue and the second extract are obtained by filtration, and the second extract is concentrated at 45° C. to obtain a second thick paste;

[0059] The first thick paste and the second thick paste are combined to obtain a total thick paste, anhydrous ethanol is added to the total thick paste to make the alcohol content reach 65%, and the mixture is stirred evenly. After standing for 24 hours, the supernatant is taken, and the sediment is centrifuged at 9° C. and 6000 rpm for 15 minutes. The supernatant obtained by centrifugation and the supernatant obtained by standing are mixed, and then concentrated at 60° C. to obtain an unpurified extract, and then redistilled water is added, and the volume ratio of the extract to the redistilled water is 1:10, and the mixture is stirred evenly, and the mixture is stood, centrifuged and concentrated again according to the above conditions to purify and obtain a terminalia chebula thick paste;

[0060] S32: The preparation process of safflower thick paste is the same as that of terminalia chebula thick paste; specifically:

[0061] 200 g of safflower was crushed, and then added to ethanol solution one for heating and reflux, the mass volume ratio of safflower and ethanol solution one was 1 g:8 mL, the concentration of ethanol solution one was 80 wt%, the heating temperature was 90° C., the reflux times were twice, and the reflux time each time was 2 h. After the alcohol extraction was completed, the residue and the extract one were obtained by filtration, and the extract one was concentrated at 45° C. to obtain a first thick paste;

[0062] The residue is added into redistilled water for decoction, the mass volume ratio of the residue to the redistilled water is 1 g: 10 mL, and the decoction is performed twice, each time for 1 hour. After the decoction is completed, the residue and the second extract are obtained by filtration, and the second extract is concentrated at 45° C. to obtain a second thick paste;

[0063] The first thick paste and the second thick paste are combined to obtain a total thick paste, anhydrous ethanol is added to the total thick paste to make the alcohol content reach 65%, and the mixture is stirred evenly. After standing for 24 hours, the supernatant is taken, and the sediment is centrifuged at 9°C and 6000rpm for 15 minutes. The supernatant obtained by centrifugation and the supernatant obtained by standing are mixed, and then concentrated to obtain an unpurified extract, and then redistilled water is added, and the volume ratio of the extract to the redistilled water is 1:10, and the mixture is stirred evenly, and the mixture is stood, centrifuged and concentrated again according to the above conditions to purify and obtain a safflower thick paste;

[0064] S4: Preparation of borneol aqueous solution

[0065] According to the mass volume ratio of borneol to redistilled water of 1g:80mL, 20g of borneol was added into redistilled water and stirred to dissolve, and a borneol aqueous solution was obtained;

[0066] S5: Extraction of artificial musk and artificial bear bile

[0067] S51: adding 1 g of artificial musk to ethanol solution 2 for heating and reflux, the mass volume ratio of artificial musk to ethanol solution 2 is 1 g: 15 mL, the concentration of ethanol solution 2 is 95 wt %, the heating temperature is 90° C., the reflux times are three times, and the reflux time each time is 2 h. After the alcohol extraction is completed, filtering to obtain a filtrate, and concentrating the filtrate at 45° C. to obtain 10 mL of artificial musk concentrate;

[0068] S52: The preparation process of the artificial bear bile concentrate is the same as the preparation process of the artificial musk concentrate; the details are as follows:

[0069] 1 g of artificial bear bile was added to ethanol solution 2 for heating and reflux, the mass volume ratio of artificial bear bile to ethanol solution 2 was 1 g: 15 mL, the concentration of ethanol solution 2 was 95 wt%, the heating temperature was 90° C., the reflux times were three times, and the reflux time each time was 2 h. After the alcohol extraction was completed, the filtrate was filtered to obtain a filtrate, and the filtrate was concentrated at 45° C. to obtain 10 mL of artificial bear bile concentrate;

[0070] S6: Preparation of Tibetan medicine composition

[0071] S61: The raw materials of the Tibetan medicine composition also include Tween-80, sodium chloride, phenoxyethanol and triethanolamine;

[0072] S62: Add Tween-80 to the artificial musk concentrate and the artificial bear bile concentrate respectively, wherein the amount of Tween-80 added accounts for 0.2% of the mass of the Tibetan medicine composition, and after mixing evenly, add the borneol aqueous solution in step S4 to obtain a mixed solution for standby use;

[0073] S63: Combine the prepared Berberis bark paste, Terminalia chebula paste, Carthamus tinctorius paste and mixed solution in a 5000mL beaker, add deionized water to 4000mL, stir evenly, centrifuge at 9°C, 7100rpm for 15min, take the supernatant, add deionized water to 4000mL to obtain a Tibetan medicine combination extract, add 0.9% sodium chloride (36g), 1% phenoxyethanol (40mL) and 1% triethanolamine (40mL) in sequence to the Tibetan medicine combination extract, stir evenly, centrifuge at 9°C, 7100rpm for 15min, take the supernatant, and then sterilize to obtain a Tibetan medicine composition.

[0074] Example 2

[0075] The difference between this embodiment and embodiment 1 is that the raw material composition design of step S1 is that the mass ratio of berberis bark, terminalia chebula, safflower, borneol, artificial bear gall and artificial musk is 250:250:200:20:1:1, and its total mass is the same as that of embodiment 1.

[0076] Comparative Example 1

[0077] The difference between this comparative example and Example 1 is that in the raw material composition design of step S1, the raw materials of the composition of this comparative example do not include berberis bark, and the mass ratio of terminalia chebula, safflower, borneol, artificial bear bile and artificial musk is 200:200:20:1:1, and its total mass is the same as that of Example 1.

[0078] Comparative Example 2

[0079] The difference between this comparative example and Example 1 is that in the raw material composition design of step S1, the raw materials of the composition of this comparative example do not include terminalia chebula, and the mass ratio of berberis bark, safflower, borneol, artificial bear bile and artificial musk is 300:200:20:1:1, and its total mass is the same as that of Example 1.

[0080] Comparative Example 3

[0081] The difference between this comparative example and Example 1 is that in the raw material composition design of step S1, the raw materials of the composition of this comparative example do not include artificial bear bile, and the mass ratio of berberis bark, terminalia chebula, safflower, borneol and artificial musk is 300:200:200:20:1, and its total mass is the same as that of Example 1.

[0082] Comparative Example 4

[0083] The difference between this comparative example and Example 1 is that no Tibetan medicine composition is added. The specific preparation method is as follows:

[0084] Take 500mL of redistilled water in a 1000mL beaker, add 4.5g of sodium chloride, 5mL of phenoxyethanol and 5mL of triethanolamine in sequence, stir and mix with an electric stirrer, put the prepared solution into a 50mL centrifuge tube, centrifuge it in a high-speed centrifuge at 9°C, 7100rpm for 15min, take the supernatant, put the supernatant into a clean and spare 500mL sterilized bottle, put it in a high-pressure sterilizer for sterilization for 3 hours, then tighten the bottle cap and take it out.

[0085] Test example

[0086] (1) The pharmaceutical compositions prepared in Example 1, Example 2, Comparative Example 1, Comparative Example 2, Comparative Example 3 and Comparative Example 4 were prepared at raw drug concentrations of 0.25 mg / mL, 0.5 mg / mL, 1 mg / mL and 2 mg / mL, and were respectively intervened in human nasal mucosal epithelial cells for 24 hours, and the cell viability was measured.

[0087] The test results are as follows:

[0088] like Figure 1 As shown, after 24 hours of action of the pharmaceutical compositions of Example 1, Example 2, Comparative Example 1, Comparative Example 2, Comparative Example 3 and Comparative Example 4 at 1 mg / mL and 2 mg / mL on human nasal mucosal epithelial cells, the cell viability was significantly decreased compared with the normal group (p<0.05). At 0.5 mg / mL, except for Comparative Example 2, the cell viability of Example 1, Example 2, Comparative Example 1, Comparative Example 3 and Comparative Example 4 after action on human nasal mucosal epithelial cells for 24 hours were 96.382%, 100.243%, 99.474%, 98.158% and 103.759%, respectively, which was not significantly different from the normal group (p>0.05). The above results show that, except for Comparative Example 2, each pharmaceutical composition has no obvious cytotoxicity at a concentration lower than 0.5 mg / mL.

[0089] (2) Establishment of inflammation model: Nasal epithelial cells were stimulated with lipopolysaccharide (LPS) (Beijing Solebow Technology Co., Ltd., CAS: 93572-42-0) at different concentrations (0, 1, 5, 10 μg / ml), and the levels of inflammatory factors (IL-6, TNF-α) were measured.

[0090] The test results are as follows:

[0091] like Figure 2 As shown, 5 μg / mL and 10 μg / mL LPS caused a significant increase in the levels of inflammatory factors (IL-6, TNF-α) in the culture supernatant of nasal mucosal epithelial cells (p<0.05) in a dose-dependent manner.

[0092] (3) Effect evaluation: After pre-treating cells with each drug composition for 24 hours, nasal mucosal epithelial cells were stimulated with 10 μg / ml LPS, and the levels of inflammatory factors (IL-6, TNF-α) were measured.

[0093] The test results are as follows:

[0094] After pretreatment with 0.5 mg / mL of each pharmaceutical composition, Example 1, Example 2, and Comparative Example 3 could significantly reduce the levels of IL-6 and TNF-α in the culture supernatant of nasal epithelial cells mediated by LPS (p<0.05). Figure 3 , but the reduction degree of Example 1 is the largest. It shows that the 0.5 mg / mL Tibetan medicine composition has a good effect on treating rhinitis, especially when the mass ratio of berberis bark, terminalia chebula, safflower, borneol, artificial bear gall and artificial musk is 300:200:200:20:1:1, the effect is the best.

[0095] (4) Clinical efficacy evaluation

[0096] ① In Yushu People's Hospital and Xihang Street Health Service Community, a Tibetan medicine composition (Example 1) of 6 mg / mL (raw drug concentration) was used, and the nasal cavity was sprayed 3 times a day, once in the morning, noon and evening, and each spray was 3 times. Clinical efficacy was observed in 143 patients with rhinitis. Among the 143 patients, there were 98 males and 45 females; the average age was (54 ± 2) years old; the average course of disease was (25 ± 2) months.

[0097] ②Observation indicators

[0098] Assessment of quality of life: The allergic rhinitis quality of life scale was used to assess the quality of life of the children. The scale evaluates the children's daily work, social activities, sleep and other dimensions, and is divided into 5 levels according to the severity, with scores ranging from 0 to 4 points respectively; the higher the score, the more serious the impact of the disease on the children's daily life. The changes in the allergic rhinitis quality of life scale scores before and after treatment were observed.

[0099] ③ Subjective score of symptom severity: VAS scoring method was used to score the subjective feelings of the patients' sneezing, nasal congestion, runny nose, and nasal itching. The children or parents subjectively evaluated the impact of the symptoms before and after treatment. 0 points means no impact on life and work, 1-3 points means slight impact on work, 4-6 points means impact on work but not life, and 7-10 points means severe impact on work and life. The changes in VAS scores of symptom severity before and after treatment were observed.

[0100] ④Efficacy evaluation criteria. The efficacy evaluation criteria were formulated with reference to the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis in China (2022, Revised Edition)" and the "Guidelines for Clinical Research of New Chinese Medicines (Trial)", that is, the efficacy was evaluated according to the changes in the symptom improvement scores before and after treatment. Statistical methods SPSS25.0 statistical software was used for statistical analysis of the data. The data that conformed to the normal distribution of the quantitative data were expressed as mean ± standard deviation (x ± s). The paired sample t test was used for comparison before and after treatment within the group. Both bilateral tests were used, and P < 0.05 indicated that the difference was statistically significant.

[0101] ⑤Observation results

[0102] The comparison of the scores of the allergic rhinitis quality of life assessment scale before and after treatment showed that the scores of the scale after treatment were significantly lower than those before treatment (P < 0.0001). The specific results are shown in Table 1. The VAS scores of the severity of the symptoms (including sneezing, nasal congestion, runny nose, and nasal itching) of the patients before and after treatment were significantly lower than those before treatment (P < 0.01). The specific results are shown in Table 1.

[0103] Table 1 Comparison of patients' quality of life and symptom assessment scale scores before and after treatment

[0104] Evaluation indicators Number of examples / example Before treatment After treatment P-value Quality of Life 143 3±1.34 1±2.22 0.0001 symptom 143 8±3.22 2±2.16 0.001

[0105] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.

Claims

1. A Tibetan medicinal composition for treating rhinitis, characterized in that: The raw materials of the Tibetan medicine composition include barberry bark, terminalia chebula, safflower, borneol, artificial bear bile and artificial musk. The mass ratio of barberry bark, terminalia chebula, safflower, borneol, artificial bear bile and artificial musk is (250~350): (150~250): (150~250): (15~25): (0.5~3): (0.5~3).

2. A Tibetan medicinal composition for treating rhinitis according to claim 1, characterized in that: The mass ratio of berberis bark, terminalia chebula, safflower, borneol, artificial bear bile and artificial musk is 300:200:200:20:1:

1.

3. A Tibetan medicinal composition for treating rhinitis according to claim 1, characterized in that: The raw materials of the Tibetan medicine composition also include Tween-80, sodium chloride, phenoxyethanol and triethanolamine.

4. A method for preparing a Tibetan medicinal composition for treating rhinitis according to any one of claims 1 to 3, characterized in that: The following steps are involved: S1: Preparation of Berberis bark paste The berberis bark coarse powder is added into purified water for water extraction, and then concentrated and purified to obtain a berberis bark thick paste; S2: Preparation of Terminalia chebula paste and safflower paste The terminalia chebula is crushed, and then added into an ethanol solution 1 for heating and reflux, after the alcohol extraction is completed, the residue and the extract 1 are obtained by filtering, and the extract 1 is concentrated to obtain a first thick paste; The medicinal residue is added into redistilled water for decoction, after the decoction is completed, the residue and the second extract are obtained by filtering, and the second extract is concentrated to obtain a second thick paste; The first thick paste and the second thick paste are combined to obtain a total thick paste, and the total thick paste is purified to obtain a terminalia chebula thick paste; The preparation process of safflower thick paste is the same as that of terminalia chebula thick paste; S3: Preparation of borneol aqueous solution Add borneol into redistilled water and stir to dissolve to obtain a borneol aqueous solution; S4: Extraction of artificial musk and artificial bear bile Adding artificial musk into the second ethanol solution and heating it under reflux, filtering to obtain a filtrate after the alcohol extraction is completed, and concentrating the filtrate to obtain an artificial musk concentrate; The preparation process of artificial bear bile concentrate is the same as that of artificial musk concentrate; S5: Preparation of Tibetan medicine composition Add Tween-80 to the artificial musk concentrate and the artificial bear bile concentrate respectively, mix them evenly, and then add the borneol aqueous solution in step S3 to obtain a mixed solution for later use; The berberis bark paste, the terminalia chebula paste, the safflower paste and the mixed solution are combined, redistilled water is added, the mixture is stirred evenly, the supernatant is obtained by centrifugation, and redistilled water is added again to obtain a Tibetan medicine combination extract, sodium chloride, phenoxyethanol and triethanolamine are added to the Tibetan medicine combination extract, the mixture is stirred evenly, the supernatant is obtained by centrifugation, and then the mixture is sterilized to obtain a Tibetan medicine composition.

5. The method for preparing the Tibetan medicinal composition for treating rhinitis according to claim 4, characterized in that: In step S1, the solid-liquid ratio of berberis bark coarse powder and purified water is 1 g: (15-25) mL. After three water extractions, the liquids are combined and then heated and concentrated at 40-80° C. to obtain an extract. Then, redistilled water is added to the extract, heated in a water bath at 40-80° C. to dissolve, and then concentrated and purified to obtain a berberis bark thick paste.

6. The method for preparing the Tibetan medicinal composition for treating rhinitis according to claim 4, characterized in that: In step S2, the mass volume ratio of terminalia chebula and ethanol solution one is 1 g: (6-10) mL, the concentration of ethanol solution one is 75-85 wt %, the heating temperature is 85-95° C., the number of reflux times is more than two times, each reflux time is 2-3 h, and the concentration temperature of extract one is 40-80° C.; The mass volume ratio of the medicinal residue and redistilled water is 1g: (8~15)mL. The extract is decocted twice, each time for 1~3h. The concentration temperature of the second extract is 40~80℃.

7. The method for preparing the Tibetan medicinal composition for treating rhinitis according to claim 4, characterized in that: In step S2, the purification process of the total thick paste is as follows: Add anhydrous ethanol to the total thick paste to make the alcohol content reach 60-70%, stir evenly, let it stand for 12-48 hours, take the supernatant, centrifuge the precipitate at 5-10°C and 5000-8000rpm for 10-20min, mix the supernatant obtained by centrifugation and the supernatant obtained by standing, then concentrate, add redistilled water and stir evenly, let it stand, centrifuge and concentrate again to obtain terminalia chebula thick paste or safflower thick paste.

8. The method for preparing the Tibetan medicinal composition for treating rhinitis according to claim 4, characterized in that: In step S3, the mass volume ratio of borneol to redistilled water is 1 g: (60-100) mL.

9. The method for preparing the Tibetan medicinal composition for treating rhinitis according to claim 4, characterized in that: In step S4, the extraction process of artificial musk is the same as the extraction process of artificial bear bile; The mass volume ratio of artificial musk and ethanol solution 2 is 1g: (10~20)mL, the concentration of ethanol solution 2 is 90~98wt%, the heating temperature is 85~95℃, the reflux times is more than twice, each reflux time is 2~3h, and the concentration temperature is 40~80℃.

10. The method for preparing a Tibetan medicinal composition for treating rhinitis according to claim 3, characterized in that: In step S5, the added amounts of Tween-80, sodium chloride, phenoxyethanol and triethanolamine account for 0.1-0.3%, 0.5-1.5%, 0.5-2% and 0.5-2% of the total amount of the Tibetan medicine combination extract in a crude drug amount of 1 g / mL, respectively.

Images